Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telomir Pharmaceuticals, Inc. ( (TELO) ) has shared an announcement.
On July 17, 2025, Telomir Pharmaceuticals announced preclinical results showing that its lead candidate, Telomir-1, effectively reverses epigenetic gene silencing of STAT1 in human prostate cancer cells, outperforming chemotherapy and Rapamycin. This breakthrough suggests Telomir-1’s potential to enhance immune recognition and tumor sensitivity to treatments without promoting tumor progression, marking a significant advancement in cancer therapy.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing therapeutic solutions across multiple areas such as oncology, Wilson’s disease, age-related macular degeneration, autism spectrum disorder, and dysphonia. The company is actively engaged in preclinical development and aims to advance its lead candidate, Telomir-1, into clinical development.
Average Trading Volume: 265,458
Technical Sentiment Signal: Sell
Current Market Cap: $33.63M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.